A Phase 3, Multicenter, Randomized, Double-Blind, 24-Week Study of the Clinical and Antiviral Effect of S-217622 Compared With Placebo in Non-Hospitalized Participants With COVID-19

ClinicalTrials.gov · COMPLETED, 2024

2,093 participants

Abstract

The main aim of this study is to evaluate the efficacy of S-217622 versus placebo among outpatient adults with mild and moderate COVID-19 starting intervention within 3 days of symptom onset.

Conditions: SARS-CoV-2 Infection.

Primary outcome: Time to Sustained Symptom Resolution.

Enrollment: 2093 participants.

How strong is the evidence?

Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 2,093 participants or records.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

• ClinicalTrials.gov
• Publisher page

Related studies

• Chaos and quantum thermalization Physical review. E, Statistical physics, plasmas, fluids, and related interdisciplinary topics, 1994
• The Dalton quantum chemistry program system Wiley Interdisciplinary Reviews. Computational Molecular Science, 2013
• Cord Blood Leptin and Adiponectin as Predictors of Adiposity in Children at 3 Years of Age: A Prospective Cohort Study Pediatrics, 2009
• Quantitative metabolomics by H-NMR and LC-MS/MS confirms altered metabolic pathways in diabetes PloS one, 2010
• Stable adiabatic quantum batteries Physical Review E, 2019
• A novel self-lipid antigen targets human T cells against CD1c(+) leukemias The Journal of experimental medicine, 2014

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free